Oxford Nanopore Technologies: John O'Higgins, Clive Brown
John O'Higgins and Clive Brown have joined the board of directors of Oxford Nanopore Technologies, the company said this week. According to a regulatory filing, the appointments were made last September. Brown is the company's chief technology officer. O'Higgins, who joined the board as a non-executive director, is the former CEO of Spectris, an instrumentation and controls company. He holds non-executive roles at several other companies and is a member of the corporate advisory board of Great Ormond Street Hospital Charity in the UK.
Transplant Genomics: John Holman
Mansfield, Massachusetts-based Transplant Genomics has appointed John Holman as VP of Medical Affairs. He will replace Roy First, who will continue working as senior clinical advisor. Prior to TGI, Holman served as VP of Immunology and Translational Medicine at Quark Pharmaceuticals. He has also served as VP of clinical research at Myriad Genetics for three years. Prior to Myriad, Holman served as executive medical director as Astellas.
Bio-Rad Laboratories: Dara Grantham Wright
Bio-Rad Laboratories has appointed Dara Grantham Wright as executive vice president of its clinical diagnostics group. She will replace John Hertia, who retired Dec. 31, 2019. Grantham Wright most recently served as VP and general manager of the protein and cell analysis biosciences division at Thermo Fisher Scientific. She has also held senior positions at Affymetrix, Boreal Genomics, and Becton Dickinson.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.